Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Karyopharm Therapeutics (KPTI) Long-Term Investments (2016 - 2021)

Karyopharm Therapeutics (KPTI) has disclosed Long-Term Investments for 8 consecutive years, with $2.0 million as the latest value for Q3 2021.

  • For the quarter ending Q3 2021, Long-Term Investments fell 94.91% year-over-year to $2.0 million, compared with a TTM value of $2.0 million through Sep 2021, down 94.91%, and an annual FY2020 reading of $24.2 million, up 1101.14% over the prior year.
  • Long-Term Investments was $2.0 million for Q3 2021 at Karyopharm Therapeutics, roughly flat from $2.0 million in the prior quarter.
  • Across five years, Long-Term Investments topped out at $48.9 million in Q2 2020 and bottomed at $2.0 million in Q4 2018.
  • Average Long-Term Investments over 5 years is $19.5 million, with a median of $10.3 million recorded in 2018.
  • The sharpest move saw Long-Term Investments skyrocketed 1847.13% in 2020, then tumbled 95.89% in 2021.
  • Year by year, Long-Term Investments stood at $29.4 million in 2017, then tumbled by 93.19% to $2.0 million in 2018, then grew by 0.75% to $2.0 million in 2019, then surged by 1101.14% to $24.2 million in 2020, then tumbled by 91.72% to $2.0 million in 2021.
  • Business Quant data shows Long-Term Investments for KPTI at $2.0 million in Q3 2021, $2.0 million in Q2 2021, and $7.7 million in Q1 2021.